Reversal of Aging of Human Cartilage, Restoring Youthfulness; the First of Its Kind Feat by Edogawa Hospital, Japan.
Cartilage of the knee joint, when severely damaged by age related wear and tear or injury or osteoarthritis, which is removed and usually discarded, during joint replacement surgery, now could be rejuvenated, becoming a potential source of cells for cell therapy through a disruptive technology that reverses aging, confirmed by Senescence associated ß-Galactosidase, p16 and p21, markers, published in Scientific Reports (www.nature.com/articles/s41598-021-93607-9), a Nature journal. A conversation between (Late) Prof. Masatoshi Koshiba, (Nobel Laureate, 2002) and Dr. Masahiro Katoh on whether his aging joints could be rejuvenated, inspired orthopedician Dr Shojiro Katoh to develop a path breaking EELS-TALC technique (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes), making this accomplishment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005420/en/
Prof. Masatoshi Koshiba (Nobel Laureate; Sitting Rt.) who initiated the idea of restoring youthfulness of cells in the lab with Dr Masahiro Katoh (Sitting Lt; Chairman, Edogawa Hospital), who accomplished Prof. Koshiba’s wishes, helped by Dr Shojiro Katoh (Standing Rt; President, Edogawa Hospital), led team including Dr. Samuel JK Abraham (Standing Lt) (Photo: Business Wire)
Aging of human body, its organs, tissues and cells is irreversible and in the lab environments, aging is much faster than inside the body. However, EELS-TALC technology has disrupted this conventional belief by making tissues younger, through tissue engineering in a chemically synthesized polymer scaffold, under physical maneuver of orbital shaking in the lab, without genetic manipulation or animal derived products, thus paving way to solutions that, when similar environment is made available inside the body, such reversal of aging might be possible.
EELS TALC cultured chondrocytes have all ideal characteristics, worth recommending as the most suitable in ACI and MACI treatments:
(i) Yielding Hyaline cartilage native to articular joints:
(ii) Hyaluronic acid enrichment, ideal for better healing:
(iii) Enhanced miRNA140, a hall mark of healthy cartilage:
(iv) Chondroprogenitors, mesenchymal stem cells grown from damaged tissues:
(v) Pluripotency marker expression and tissue like growth:
(vi) Increased telomere length, proving youthfulness:
Presented at meetings of British Society of Developmental Biology - Genetics Society & British Society of Gerontology; 2021.
(vii) Lower SA-ß-Gal, p16, p21; confirming the reversal of aging:
(viii) Pre-clinical studies proving, success in vivo:
EELS-TALC method is safe as it does not involve genomic alterations, oncogenes, viruses, or complex growth factors. Now, Dr. Katoh is evaluating ideal transportation of tissues and cells between the hospital and the lab based on earlier reported OPTRACT method (https://doi.org/10.1007/s10529-021-03116-y) and additional safety parameters, supported by EELS, JBM Inc, GN Corporation and NCRM, India, before starting clinical studies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Samuel JK Abraham
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IC Markets Records Highest Ever Monthly Trading Volume of USD 1.016 Trillion in November7.12.2021 02:29:00 CET | Press release
IC Markets has recorded its highest ever monthly trading volume, following a surge in trading volume across all asset classes in November. According to IC Markets the record month is a result of its product diversification, growth into new markets, an increased client retention rate and optimum trading conditions which led to clients taking advantage of high volatility in the markets. The results follow last year’s unprecedented growth across the global retail trading industry, with IC Markets reporting $9.32 trillion in trading volume for the year. The trading volumes for November eclipsed the previous high of $1 trillion achieved in March this year. IC Markets CEO Andrew Budzinski commented, “We are delighted to be bringing more traders across a growing number of markets a greater choice of trading instruments so they can diversify their portfolio whilst taking advantage of the optimum trading conditions.” “Our traders are staying with us to take advantage of the highly competitive s
Conviva Teams With Experian to Expand Audience Measurement Capabilities for Streaming Publishers7.12.2021 00:00:00 CET | Press release
Conviva, the continuous measurement platform for streaming media, has teamed with Experian, the leading global information services company, to provide streaming publishers and their ecosystem partners with the industry’s most advanced audience segmentation data, a key step towards solving the streaming industry’s global measurement challenge. The combination of Conviva’s first-party, census-level streaming data and Experian’s unparalleled demographic data empowers publishers to easily provide advertisers with the most detailed and accurate audience insights available, including audience content preferences, viewer behavior patterns, ad exposures and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005840/en/ Experian + Conviva (Graphic: Business Wire) The solution is bolstered by the integration of Experian marketing data into Conviva’s newly expanded streaming audience measurement platform, which includes Stream
CSC Reaches Conditional Agreement to Acquire Intertrust N.V.6.12.2021 15:45:00 CET | Press release
CSC, the world’s leading provider of business, legal, tax, and digital brand services, announces a conditional agreement has been reached on a recommended public offer for all issued and outstanding ordinary shares of Intertrust. The combination of CSC and Intertrust creates a clear and differentiated leader for clients on an international scale, built on the combined strengths of each other’s global teams with complementary geographic and service offerings. Founded in 1899, with headquarters in Wilmington, Delaware, USA, and with 3,000 employees in 13 countries across the globe, CSC is the trusted partner for more than 180,000 corporate clients—including 90% of the Fortune 500®—as well as nearly 10,000 law firms and more than 3,000 financial institutions. CSC’s success is built on its ability to provide its clients with best-in-class solutions to efficiently manage and enable key business processes. Since 2002, CSC has made more than 25 strategic acquisitions, building a solid reputat
Wipro and Celonis Launch Supply Chain Command Center Solution6.12.2021 14:24:00 CET | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, and Celonis, the global leader in execution management, today announced the launch of the Supply Chain Command Center to help organizations drive supply-chain transformation. The solution enables companies to automatically identify and fix process bottlenecks and inefficiencies, gain powerful business insights, open new growth opportunities, manage risks and maintain business continuity even in disruptive times. It improves the supply-chain efficiency by working across the four stages - planning, sourcing, developing and delivering. The Supply Chain Command Center combines a range of business-critical capabilities, from process KPI benchmarks to process optimization in transformation programs. Enterprises can leverage ready-to-use models for process maturity level assessment, custom code analysis, and automation opportunities. The solution is of
Local Loyal, Spice Seeking, Mindful Mixologists - These Are the Spirits Consumers of 2022, According to the Annual Bacardi Cocktail Trends Report6.12.2021 13:00:00 CET | Press release
Bacardi Limited, theworld's largest privately-held spirits company, releases its third annual Bacardi Cocktail Trends Report, looking ahead at the key trends impacting the business of cocktails in 2022. The report is created in collaboration withThe Future Laboratory (TFL) and draws from Bacardi-led and external research to unveil the undercurrents transforming everything from drinks desired, flavor expectations, and imbibing occasions through to ethical action and ways of creating cocktails. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005158/en/ The third annual Bacardi Cocktail Trends Report spotlights the macro-trends defining how, what, where, and why consumers are sipping spirits in 2022. (Graphic: Business Wire) “As 2022 brings new perspective, people are coming together with a strong desire to ‘Make Moments Matter’. At Bacardi, we are driven by this purpose – with a family of premium spirit brands that are un
Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis6.12.2021 10:00:00 CET | Press release
Galderma today announced that the Journal of Allergy and Clinical Immunology has published gene expression data that demonstrate the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis (PN), confirming the potential of nemolizumab as a major player in the treatment of PN, effectively reducing both pruritus and severity of skin lesions in PN patients. “Transcriptome data is an important step in validating the therapeutic effect of nemolizumab through a deeper understanding of the mode of action at a cellular level. With these data, we are advancing dermatology and contributing to improving our understanding of PN. These data emphasize that nemolizumab may have a key role to play for patients with moderate to severe PN. This will be confirmed by our ongoing nemolizumab Phase 3 studies in PN.” Dr. Baldo Scassellati Sforzolini Global Head of R&D, GALDERMA PN is a rare, potentially debilitating, chronic skin condition wit
iProov and Eurostar Launch Trial to Provide Contactless Travel at London St Pancras International6.12.2021 08:00:00 CET | Press release
iProov, the world leader in biometric face authentication technology, and Eurostar, the high-speed passenger rail service linking the UK with mainland Europe, have announced that their trial of a contactless fast-track service, SmartCheck, is now live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211205005029/en/ iProov and Eurostar announce contactless travel trial is live at London St Pancras International (Photo: Business Wire) SmartCheck enables passengers to complete secure ticket verification and UK exit check on their mobile devices prior to travel. As part of the trial, Business Premier and Carte Blanche ticket holders will be able to scan their identity documentation using their iPhones before arriving at the station, completing a brief biometric face scan to verify that they are the genuine holder of the identity document. The biometric face verification, which uses iProov’s Genuine Presence Assurance technology,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom